Indegene Limited (BOM:544172)
India · Delayed Price · Currency is INR | Market Cap | 129.95B -9.8% |
| Revenue (ttm) | 35.11B +23.6% |
| Net Income | 4.01B -1.4% |
| EPS | 16.62 -2.4% |
| Shares Out | n/a |
| PE Ratio | 32.40 |
| Forward PE | 25.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,112 |
| Open | 516.20 |
| Previous Close | 517.40 |
| Day's Range | 516.20 - 535.00 |
| 52-Week Range | 414.90 - 596.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 592.43 (+11.24%) |
| Earnings Date | Jul 31, 2026 |
About Indegene
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technolo... [Read more]
Financial Performance
In fiscal year 2026, Indegene's revenue was 35.11 billion, an increase of 23.64% compared to the previous year's 28.39 billion. Earnings were 4.01 billion, a decrease of -1.38%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for 544172 stock is "Buy." The 12-month stock price target is ₹592.43, which is an increase of 11.24% from the latest price.
News
Indegene Slides: Investor presentation
Indegene has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Indegene Transcript: Q4 25/26
Record revenue and EBITDA growth driven by deepening customer relationships, GenAI-led innovation, and strategic acquisitions. Strong cash flows and improved margins expected as investments are absorbed, with a robust pipeline and industry tailwinds supporting multi-year growth.
Indegene Quarterly report: Q4 2026
Indegene has published its Q4 2026 quarterly earnings report on April 29, 2026.
Indegene Slides: Q4 2026
Indegene has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 29, 2026.
Indegene Transcript: Q3 25/26
Q3 FY2026 delivered 30.8% year-on-year revenue growth and 18.5% adjusted EBITDA margin, driven by large AI-enabled deal wins and successful BioPharm integration. Management expects margins to improve and strong cash flows to continue as synergies materialize.
Indegene Quarterly report: Q3 2026
Indegene has published its Q3 2026 quarterly earnings report on January 29, 2026.
Indegene Slides: Q3 2026
Indegene has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 29, 2026.
Indegene Transcript: Q2 25/26
Q2 revenue grew 17.1% YoY with strong deal wins and robust pipeline, despite near-term margin compression from investments in GenAI and acquisitions. Industry headwinds from U.S. policy changes are manageable, and management expects margins to recover as growth accelerates.
Indegene Quarterly report: Q2 2026
Indegene has published its Q2 2026 quarterly earnings report on October 30, 2025.
Indegene Slides: Q2 2026
Indegene has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 30, 2025.
Indegene Transcript: Q1 25/26
Q1 FY2026 saw 12.5% year-over-year revenue growth, stable 20.2% EBITDA margin, and strong cash reserves. Enterprise segments drove growth, while Brand Activation faced project deferrals. AI initiatives and Tectonic are gaining traction, with a robust deal pipeline and M&A focus.
Indegene Quarterly report: Q1 2026
Indegene has published its Q1 2026 quarterly earnings report on July 31, 2025.
Indegene Slides: Q1 2026
Indegene has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 31, 2025.